Anthony Cheung
Founder en ENGENE HOLDINGS INC. .
Fortuna: 2 M $ al 31/03/2024
Perfil
Anthony T.
Cheung is the founder of enGene Holdings, Inc. (founded in 2023) and currently holds the title of Chief Technology Officer.
Dr. Cheung is also the founder of enGene,.
Inc...
Dr. Cheung's education history includes an undergraduate degree from the University of British Columbia and a doctorate degree from Tulane University School of Medicine.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ENGENE HOLDINGS INC.
0.24% | 18/03/2024 | 102 873 ( 0.24% ) | 2 M $ | 31/03/2024 |
Cargos activos de Anthony Cheung
| Empresas | Cargo | Inicio |
|---|---|---|
| ENGENE HOLDINGS INC. | Founder | 24/04/2023 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Founder | - |
Formación de Anthony Cheung.
| University of British Columbia | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
| enGene Holdings, Inc. |
- Bolsa de valores
- Insiders
- Anthony Cheung
